Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.

This article discusses frontal fibrosing alopecia, noting potential connections to lichen planopilaris, but reports no new clinical findings.

This study found that topical bimatoprost significantly improved eyelash growth in individuals with idiopathic and chemotherapy-induced eyelash hypotrichosis compared to a vehicle treatment.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

This study, using modified Delphi panels, provided consensus recommendations for managing alpelisib-induced hyperglycemia and rash, advising prophylactic metformin starting for certain risk groups and the use of nonsedating H1 antihistamines and topical steroids for initial rash management.

In this study, the researchers evaluated the exposure-response relationship of ritlecitinib on eyebrow and eyelash regrowth and concluded that the established models justify selecting a 50 mg dose for patients with severe alopecia areata, while highlighting differing efficacy among evaluation methods.

This source reports that clascoterone cream, a topical androgen receptor inhibitor, has shown effectiveness in treating facial acne vulgaris in patients 12 and older, with clinical trials indicating a favorable safety profile compared to systemic treatments, and potential for broader dermatological applications.

In this study, Ritlecitinib was reported as a newly approved treatment for alopecia areata that can be used in patients aged 12 and older; after 24 weeks, it resulted in 80% or more scalp hair coverage in treated patients compared to a placebo.

This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.

This study found that ALRN-6924 effectively protected human hair follicles from cyclophosphamide-induced damage in an ex vivo setting, suggesting it may reduce both acute and permanent chemotherapy-induced alopecia.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

Bexarotene gel shows promise as a new treatment for alopecia areata.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.

This review discusses topical and intralesional treatments for alopecia areata, providing a management strategy based on patient age and disease severity, but reports no new clinical results.

In this case report, two adolescents developed androgenetic alopecia after treatment with anastrozole for idiopathic short stature, suggesting this potential side effect should be considered in pediatric patients using aromatase inhibitors.

This paper discusses anagen effluvium, a reversible non-scarring hair loss often triggered by certain chemotherapy drugs, but presents no new clinical results.

This study found that abrocitinib showed promising efficacy and safety in adolescents with moderate-to-severe alopecia areata, with significant hair regrowth observed over 10 months of treatment.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.

This study found that there was no significant difference in hair regrowth between clobetasol and bimatoprost for scalp alopecia areata over 12 weeks, but bimatoprost had fewer side effects and prompted earlier, more pigmented hair regrowth.

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

In this case report, a Japanese woman with both atopic dermatitis and alopecia areata showed improvement in both conditions following treatment with nemolizumab.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.